Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10382
Title: Melioidosis Causing Critical Illness: A Review of 24 Years of Experience From the Royal Darwin Hospital ICU.
Authors: Stephens, Dianne P
Thomas, Jane H
Ward, Linda M
Currie, Bart J
Affiliation: 1Department of Intensive Care, Royal Darwin Hospital, Darwin, NT, Australia. 2Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. 3Department of Infectious Diseases and Northern Territory Medical Program, Royal Darwin Hospital, Darwin, NT, Australia..
Issue Date: Aug-2016
Citation: Critical care medicine 2016-08; 44(8): 1500-5
Abstract: Melioidosis is increasing in incidence with newly recognized foci of melioidosis in the Americas, Africa, and elsewhere. This review describes the demographics, management, and outcomes of a large cohort of critically ill patients with melioidosis. Data were extracted from two prospective databases-the Menzies School of Health Research Melioidosis Database (1989-2013) and the Royal Darwin Hospital ICU Melioidosis Database (2001-2013). The Royal Darwin Hospital ICU is the only ICU in the tropical Top End of Northern Territory of Australia, an endemic area for melioidosis. The study included all patients with melioidosis admitted to Royal Darwin Hospital ICU from 1989 to 2013. From 1989 to 2013, 207 patients with melioidosis required admission to ICU. Mortality reduced from 92% (1989-1997) to 26% (1998-2013) (p < 0.001). The reduced mortality coincided with the introduction of an intensivist-led service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed melioidosis sepsis in 1998. Pneumonia was the presenting illness in 155 of 207 (75%). ICU melioidosis patients (2001-2013) had an Acute Physiology and Chronic Health Evaluation II score of 23, median length of stay in the ICU of 7 days, and median ventilation hours of 130 and one third required renal replacement therapy. The mortality for critically ill patients with melioidosis in the Top End of the Northern Territory of Australia has substantially reduced over the past 24 years. The reduction in mortality coincided with the introduction of an intensivist-led model of care, the empiric use of meropenem, and adjunctive treatment with granulocyte colony-stimulating factor in 1998.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10382
DOI: 10.1097/CCM.0000000000001668
Type: Journal Article
Subjects: APACHE
Anti-Bacterial Agents
Australia
Comorbidity
Critical Illness
Female
Granulocyte Colony-Stimulating Factor
Humans
Incidence
Intensive Care Units
Length of Stay
Male
Melioidosis
Middle Aged
Prospective Studies
Residence Characteristics
Respiration, Artificial
Socioeconomic Factors
Thienamycins
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.